About vaccines

Background SARS-CoV-2 vaccines are highly effective at preventing COVID-19-related morbidity and mortality. As no vaccine is 100% effective, breakthrough infections are expected to occur. Methods We analyzed the virological characteristics of 161 vaccine breakthrough infections in a population of 24,706 vaccinated healthcare workers (HCWs), using RT-PCR and virus culture. // 21.8.2021

A new study published in the journal mBio focuses on the role of nasal bacteria in eliciting virus-specific adaptive immunity.// 20.8.2021

Brittitutkimuksen mukaan sekä Pfizerin että Astra Zenecan koronarokotteiden tarjoama suoja koronaviruksen deltavarianttia vastaan on hieman laskenut 90 päivää toisen rokotuksen jälkeen. //19.8.2021

New research suggests that early COVID-19 vaccination saved thousands of lives and may have prevented nearly 3 million cases in just the first 5 months of 2021. // 18.8.2021

Nature Communications - Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with... // 17.8.2021

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).// 16.8.2021

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. // 16.8.2021

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system's T cells-;the heavy armor of the immune system-;according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania. // 16.8.2021

In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of neutralizing antibody responses and mediate protection against upper and lower airway infection by a range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern – even those relatively resistant to in vitro neutralization. // 16.8.2021

Objectives Immunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these patients when circulating B cells are lacking. // 13.8.2021

// 13.8.2021

Original Article from The New England Journal of Medicine — Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant // 12.8.2021

A South Australian-developed SARS-CoV-19 vaccine is preparing to progress to the final stages of human clinical trials after early animal testing confirmed its safety and effectiveness in preventing COVID-19 lung infection. // 11.8.2021

Keskustelu kolmannen koronarokotteen tarpeesta on herännyt myös Suomessa. THL:n ylilääkärin Hanna Nohynekin mukaan asiassa on vielä paljon avoimia kysymyksiä. //11.8.2021

Laumasuojan käsitteellä on yleisesti tarkoitettu viruksen kierron estämistä. Helsingin yliopiston virologian professori Olli Vapalahti sanoo, että viruksen kierto ei tule loppumaan seinään. //11.8.2021

Scientific understanding of the coronavirus variant is changing quickly. Here’s a recap of the most important findings. //11.8.2021

Experts are recommending vaccination, even if you have natural immunity from a previous infection.// 10.8.2021

As the Delta variant likely drives more cases of Covid-19 in vaccinated individuals, experts weigh in with helpful information// 10.8.2021

Antibody responses to SARS-CoV-2 variants increase after two doses of BNT162b2 vaccine in both previously infected and naïve individuals. //10.8.2021 Previously infected, fully vaccinated heath care workers in the United Kingdom — where officials allow shots to be given up to 12 weeks apart rather than the standard three or four — had antibodies that could attack variants including beta.

January – July 2021)

German company BioNTech said its vaccine developed with Pfizer works against the Delta strain and does not need to be modified yet. // 9.8.2021

An ability to build up higher concentrations of viral particles in people’s airways and mutations that might boost its ability to infect human cells could be what gives the Delta variant its evolutionary edge. //9.8.2021

Rokotetutkimuskeskuksen johtajan mielestä ensimmäisten rokotusten kattavuudesta pitää huolehtia ennen kuin aletaan miettiä kolmatta rokotekierrosta. Kolmas kierros voisi olla mahdollinen syyskuun jälkeen. //6.8.2021

This report describes COVID-19 reinfection among vaccinated and unvaccinated persons in Kentucky.// 6.8.2021

Secondary attack rates dropped from 31% to 11% if the index patient was vaccinated. //6.8.2021

They’re not perfect and they never were. But they remain the only way to end the pandemic // 6.8.2021

A new study from Japan, released as a medRxiv* preprint, describes the adverse effects associated with the vaccine. Such data is crucial in delineating the safety and efficacy of this intervention in various age groups.// 6.8.2021

In new research, scientists at Imperial College London report that double vaccinated individuals could be three times less likely than unvaccinated people to test positive for SARS-CoV-2 infection. //6.8.2021

Nature - Concerns over waning immunity and SARS-CoV-2 variants have convinced some countries to deploy extra vaccine doses — but it’s not clear to scientists whether most people need them.// 5.8.2021

Several studies report high effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe disease, however an important knowledge gap is the vaccine effectiveness against transmission (VET). // 5.8.2021